Poly(ADP-ribose) polymerase inhibition improves postischemic myocardial function after cardioplegia-cardiopulmonary bypass
- PMID: 12892811
- DOI: 10.1016/S1072-7515(03)00538-6
Poly(ADP-ribose) polymerase inhibition improves postischemic myocardial function after cardioplegia-cardiopulmonary bypass
Abstract
Background: Poly(ADP-ribose) polymerase activation has been shown to contribute to the pathogenesis of myocardial ischemia-reperfusion injury. We hypothesized that a novel poly(ADP-ribose) polymerase inhibitor, INO-1001, provides myocardial protection and improves cardiac function after regional ischemia and cardioplegia-cardiopulmonary bypass (CPB).
Study design: Pigs were subjected to 30 minutes of regional ischemia by distal left anterior descending coronary artery ligation followed by CPB (60 minutes) with hyperkalemic cardioplegia (45 minutes). The myocardium then was reperfused post-CPB for 90 minutes. After 15 minutes of ischemia, the treatment group (n = 6) received an INO-1001 bolus (1mg/kg) before a continuous infusion (1mg/kg/hour). Control pigs (n = 6) received vehicle solution. Left ventricular pressure was monitored, from which the maximum, positive first derivative of left ventricular pressure over time (+dP/dt) was calculated. Regional myocardial function in the ischemic area was determined by sonomicrometric analysis. Infarct size was measured as the percent of the ischemic area by tetrazolium staining. Myocardial sections were immunohistochemically stained for poly(ADP-ribose) as a measure of poly(ADP-ribose) polymerase activity and inhibition.
Results: Pigs treated with INO-1001 showed improvements in the +dP/dt at 60 and 90 minutes of post-CPB reperfusion (both p = 0.03) and percent segmental shortening at 30, 60, and 90 minutes of post-CPB reperfusion (p = 0.03, 0.009, and 0.03, respectively). Infarct size was decreased in the treatment group (18.5 +/- 5.7% versus 52.0 +/- 7.7%, INO-1001 versus control, p = 0.03). Poly(ADP-ribose) was reduced in myocardial sections from INO-1001-treated animals compared with controls.
Conclusions: These results suggest that INO-1001 provides myocardial protection by reducing the extent of infarction and improves cardiac function after regional ischemia and cardioplegia-CPB.
Similar articles
-
Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest.J Thorac Cardiovasc Surg. 2004 Oct;128(4):602-8. doi: 10.1016/j.jtcvs.2004.02.037. J Thorac Cardiovasc Surg. 2004. PMID: 15457162
-
Role of poly(ADP-ribose) polymerase activation in the pathogenesis of cardiopulmonary dysfunction in a canine model of cardiopulmonary bypass.Eur J Cardiothorac Surg. 2004 May;25(5):825-32. doi: 10.1016/j.ejcts.2004.01.031. Eur J Cardiothorac Surg. 2004. PMID: 15082289
-
Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size.Shock. 2010 May;33(5):507-12. doi: 10.1097/SHK.0b013e3181c4fb08. Shock. 2010. PMID: 20395771
-
Poly(ADP-ribose) polymerase activation in the reperfused myocardium.Cardiovasc Res. 2004 Feb 15;61(3):471-80. doi: 10.1016/j.cardiores.2003.09.029. Cardiovasc Res. 2004. PMID: 14962478 Review.
-
Cardioprotective effects of poly(ADP-ribose) polymerase inhibition.Pharmacol Res. 2005 Jul;52(1):34-43. doi: 10.1016/j.phrs.2005.02.017. Pharmacol Res. 2005. PMID: 15911332 Review.
Cited by
-
Activation of poly(ADP-ribose) polymerase by myocardial ischemia and coronary reperfusion in human circulating leukocytes.Mol Med. 2006 Sep-Oct;12(9-10):221-8. doi: 10.2119/2006–00055.Toth-Zsamboki. Mol Med. 2006. PMID: 17225870 Free PMC article.
-
Mitochondria as Regulators of Nonapoptotic Cell Death in Cancer.MedComm (2020). 2025 Jul 23;6(8):e70244. doi: 10.1002/mco2.70244. eCollection 2025 Aug. MedComm (2020). 2025. PMID: 40703196 Free PMC article. Review.
-
Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells.J Clin Invest. 2003 Oct;112(7):1049-57. doi: 10.1172/JCI18127. J Clin Invest. 2003. PMID: 14523042 Free PMC article.
-
A new, potent poly(ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advanced aging.J Pharmacol Exp Ther. 2004 Nov;311(2):485-91. doi: 10.1124/jpet.104.069658. Epub 2004 Jun 22. J Pharmacol Exp Ther. 2004. PMID: 15213249 Free PMC article.
-
Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure.Int J Mol Med. 2006 Feb;17(2):369-75. Int J Mol Med. 2006. PMID: 16391839 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical